• Welcome, Guest. Please login or register.
    December 11, 2019, 09:39:32 PM

  • Login with username, password and session length

Sajid's dove

Tell everyone they can now find this site by typing this into their browser:


Click to visit us on Facebook

If you have any problems registering or signing in, please send an email to: andythalpal@yahoo.com
Please do not send questions about thalassemia to this address.


Thalassemia Patients and Friends and thalpal Ā© A. Battaglia 2019

55167 Posts in 5879 Topics by 6158 Members
Latest Member: mohamohy

Forum Tip: 
Put your birthdate in your profile, under "Forum Profile Information," and it will automatically come up on our calendar.
« previous next »
Pages: 1 Go Down Print
Author Topic: Acceleron commences ACE-536 Phase 1 clinical trial in anemia  (Read 3036 times)
I wish you a speedy recovery
Junior Member
Offline Offline

Location: Kingdom of Bahrain

Gender: Male
Posts: 113

« on: September 14, 2011, 01:43:34 PM »

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases today announced that it has initiated a Phase 1 clinical study of ACE-536. ACE-536 is a ligand trap that increases red blood cells and hemoglobin by inhibiting members of the TGF-beta superfamily involved in late stages of erythropoiesis. ACE-536 is being developed for the treatment of anemia in a global collaboration with Celgene Corporation. The Phase 1 clinical trial is a multiple-dose, dose-escalating study designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ACE-536. Acceleron will receive a $7.5 million payment from Celgene for achieving this milestone event.

"ACE-536 has the potential to make a significant impact on the treatment of anemia, specifically, in diseases such as Myelodysplastic syndromes and beta-thalassemia in which the severe anemia isn't well managed by currently available therapies. By affecting production of red blood cells via a mechanism distinct from erythropoiesis stimulating agents, ACE-536 may become an option for patients for whom current therapies are ineffective," said John Knopf, Ph.D., Chief Executive Officer of Acceleron. "Acceleron's leadership in the biology of the TGF-beta superfamily proteins and our related expertise in discovering, developing and manufacturing potent biologic modulators of these proteins has enabled incredible productivity achievements in a short period of time. ACE-536 is our fourth internally discovered, developed and manufactured drug to enter human clinical trials in the past five years."

Andy Battaglia
Supreme Member
Offline Offline

Location: In my heart, Maldives

Gender: Male
Posts: 8608

Will thal rule you or will you rule thal?

« Reply #1 on: September 14, 2011, 07:28:33 PM »

It is amazing how many different approaches to treating thalassemia are under investigation and in trials. Thals need to look at this and understand how important it is to take care of themselves today, because there are so many new treatments coming that will make life so much easier. It should be a good incentive to stay alive now.


All we are saying is give thals a chance.
Junior Member
Offline Offline

Location: USA

Gender: Male
Posts: 136

« Reply #2 on: September 15, 2011, 11:22:26 AM »

True...looking forward to all these treatments....hopefully soon
Pages: 1 Go Up Print 
« previous next »
Jump to:  

Powered by MySQL Powered by PHP Powered by SMF 1.1.21 | SMF © 2015, Simple Machines Valid XHTML 1.0! Valid CSS!